Literature DB >> 9373239

Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis.

L M Martins1, P W Mesner, T J Kottke, G S Basi, S Sinha, J S Tung, P A Svingen, B J Madden, A Takahashi, D J McCormick, W C Earnshaw, S H Kaufmann.   

Abstract

Previous studies have shown that K562 chronic myelogenous leukemia cells are resistant to induction of apoptosis by a variety of agents, including the topoisomerase II (topo II) poison etoposide, when examined 4 to 24 hours after treatment with an initiating stimulus. In the present study, the responses of K562 cells and apoptosis-proficient HL-60 acute myelomonocytic leukemia cells to etoposide were compared, with particular emphasis on determining the long-term fate of the cells. When cells were treated with varying concentrations of etoposide for 1 hour and subsequently plated in soft agar, the two cell lines displayed similar sensitivities, with a 90% reduction in colony formation at 5 to 10 mu mol/L etoposide. After treatment with 17 mu mol/L etoposide for 1 hour, cleavage of the caspase substrate poly(ADP-ribose) polymerase (PARP), DNA fragmentation, and apoptotic morphological changes were evident in HL-60 cells in less than 6 hours. After the same treatment, K562 cells arrested in G2 phase of the cell cycle but otherwise appeared normal for 3 to 4 days before developing similar apoptotic changes. When the etoposide dose was increased to 68 mu mol/L, apoptotic changes were evident in HL-60 cells after 2 to 3 hours, whereas the same changes were observed in K562 cells after 24 to 48 hours. This delay in the development of apoptotic changes in K562 cells was accompanied by delayed release of cytochrome c to the cytosol and delayed appearance of peptidase activity that cleaved the fluorogenic substrates Asp-Glu-Val-Asp-aminotrifluoromethylcoumarin (DEVD-AFC) and Val-Glu-Ile-Asp-aminomethylcoumarin (VEID-AMC) as well as an altered spectrum of active caspases that were affinity labeled with N-(Nalpha-benzyloxycarbonylglutamyl-Nepsilon-biotin yllysyl) aspartic acid [(2,6-dimethylbenzoyl)oxy]methyl ketone [z-EK(bio)D-aomk]. On the other hand, the activation of caspase-3 under cell-free conditions occurred with indistinguishable kinetics in cytosol prepared from the two cell lines. Collectively, these results suggest that a delay in the signaling cascade upstream of cytochrome c release and caspase activation leads to a long latent period before the active phase of apoptosis is initiated in etoposide-treated K562 cells. Once the active phase of apoptosis is initiated, the spectrum and subcellular distribution of active caspase species differ between HL-60 and K562 cells, but a similar proportion of cells are ultimately killed in both cell lines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373239

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Comparative analysis of different methodological approaches to the in vitro study of drug-induced apoptosis.

Authors:  V D Kravtsov; T O Daniel; M J Koury
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

2.  Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression.

Authors:  R Kurdow; B Schniewind; S Zoefelt; L Boenicke; A-S Boehle; P Dohrmann; H Kalthoff
Journal:  Langenbecks Arch Surg       Date:  2005-02-22       Impact factor: 3.445

3.  Anti-incretin, Anti-proliferative Action of Dopamine on β-Cells.

Authors:  Antonella Maffei; Ann Marie Segal; Juan Carlos Alvarez-Perez; Adolfo Garcia-Ocaña; Paul E Harris
Journal:  Mol Endocrinol       Date:  2015-03-09

4.  Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases.

Authors:  X J Huang; P H Wiernik; R S Klein; R E Gallagher
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

5.  Synthesis of novel caspase inhibitors for characterization of the active caspase proteome in vitro and in vivo.

Authors:  Alexander J Henzing; Helen Dodson; Joel M Reid; Scott H Kaufmann; Robert L Baxter; William C Earnshaw
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

6.  Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.

Authors:  Anand G Patel; Karen S Flatten; Paula A Schneider; Nga T Dai; Jennifer S McDonald; Guy G Poirier; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2011-12-12       Impact factor: 5.157

7.  Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

Authors:  Ruben A Mesa; David Loegering; Heather L Powell; Karen Flatten; Sonnet J H Arlander; Nga T Dai; Michael P Heldebrant; Benjamin T Vroman; B Douglas Smith; Judith E Karp; Cynthia J Ten Eyck; Charles Erlichman; Scott H Kaufmann; Larry M Karnitz
Journal:  Blood       Date:  2005-03-22       Impact factor: 22.113

8.  Caspase-8 and caspase-3 are expressed by different populations of cortical neurons undergoing delayed cell death after focal stroke in the rat.

Authors:  J J Velier; J A Ellison; K K Kikly; P A Spera; F C Barone; G Z Feuerstein
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

9.  Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.

Authors:  Andrea E Wahner Hendrickson; Paul Haluska; Paula A Schneider; David A Loegering; Kevin L Peterson; Ricardo Attar; B Douglas Smith; Charles Erlichman; Marco Gottardis; Judith E Karp; Joan M Carboni; Scott H Kaufmann
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

10.  Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

Authors:  Judith E Karp; Karen Flatten; Eric J Feldman; Jacqueline M Greer; David A Loegering; Rebecca M Ricklis; Lawrence E Morris; Ellen Ritchie; B Douglas Smith; Valerie Ironside; Timothy Talbott; Gail Roboz; Son B Le; Xue Wei Meng; Paula A Schneider; Nga T Dai; Alex A Adjei; Steven D Gore; Mark J Levis; John J Wright; Elizabeth Garrett-Mayer; Scott H Kaufmann
Journal:  Blood       Date:  2008-12-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.